Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus placebo and adalimumab in psoriatic arthritis
NCT03104400Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in psoriatic arthritis (PsA) (5 arms), sponsored by AbbVie Inc. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03104400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104400.